ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0792

Post-mRNA Vaccine Flares in Autoimmune Inflammatory Rheumatic Diseases: Results from the COronavirus National Vaccine Registry for ImmuNe Diseases SINGapore (CONVIN-SING)

Margaret Ma1, Amelia Santosa1, Kok Ooi Kong2, Chuanhui Xu2, Gim Gee Teng1, Johnston GX Tang2, Anselm Mak3, Frank Tay1, Victoria WW Ng4, Joshua ZE Koh4, Warren Fong5, Li-Ching Chew6, Andrea Low7, annie law8, Yih Jia Poh8, Siaw Ing Yeo6, Ying Ying Leung9, Wei-Rui Goh6, Nur Emilia Roslan10, Tyng Yu Chuah10, Stanley Angkodjojo11, Thaschawee Arkachaisri12, Kai Liang Teh13, Kee Fong Phang14, Melonie Sriranganathan15, teck Choon Tan16, Peter Cheung1 and Manjari Lahiri1, 1National University Hospital, Singapore, Singapore, 2Tan Tock Seng Hospital, Singapore, Singapore, 3Division of Rheumatology, Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore, 4National University of Singapore, Singapore, Singapore, 5Singapore Health Services Pte Ltd (SHS), Singapore, Singapore, 6Singapore General Hospital, Singapore, Singapore, 7Department of Rheumatology and Immunology, Singapore General Hospital, Singapore, Singapore, 8SingHealth, Singapore, Singapore, 9Rheumatology Department, Singapore General Hospital, Singapore, Singapore, 10Sengkang General Hospital, Singapore, Singapore, 11Sengkang General Hospital / Singhealth, Singapore, Singapore, 12KK Women's and Children's Hospital, SingHealth, Singapore, Singapore, 13KK Women's and Children's Hospital, Singapore, Singapore, 14Alexandra Hospital, Singapore, Singapore, 15Changi General Hospital, Singapore, Singapore, 16Khoo Teck Puat Hospital, Singapore, Singapore

Meeting: ACR Convergence 2022

Keywords: autoimmune diseases, COVID-19, Disease Activity

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 13, 2022

Title: Infection-related Rheumatic Disease Poster

Session Type: Poster Session B

Session Time: 9:00AM-10:30AM

Background/Purpose: Published data suggest no increased rate of flare of autoimmune inflammatory rheumatic diseases (AIIRD) after COVID-19 mRNA vaccination; however, the studies are limited by small sample size, short follow up or at risk of selection bias (voluntary physician reports or patient surveys). Therefore, our aim is to study flares of AIIRD within three months of the first dose of an anti-SARS-COV2 mRNA vaccine.

Methods: A retrospective cohort study of consecutive AIIRD patients ≥ 12 years old, across 8 public hospitals in Singapore who received at least one dose of an mRNA (Pfizer/BioNTech or Moderna) vaccine. Data were censored at the first post-vaccine clinic visit when the patient had flared or if ≥ three months had elapsed since the first dose of the vaccine, whichever came first. Predictors of flare were determined by Cox proportional hazards analysis and time to flare was examined using a Nelson Aalen cumulative hazard estimate (Figure 1).

Results: 4627 patients (73.3% Chinese, 71.1% female) of median (IQR) age 61 (48, 70) years were included in the analysis (Table). 4058 (87.7%) had the Pfizer/BioNTech vaccine and 523 (11.3%) had Moderna, with a median (IQR) interval of 21 (21, 28) days between the two doses. The most common AIIRD diagnoses were Rheumatoid arthritis (1966, 42.4%), Psoriatic arthritis (486, 10.5%) and Systemic lupus erythematosus (SLE) (641, 13.8%). 2188 (47.3%) patients were in remission, 1897 (41%) in low disease activity, 480 (10.4%) in moderate disease activity and 62 (1.3%) in high disease activity. 431 (9.3%) were treated with biologics/ targeted disease modifying agents. Treatment was interrupted for vaccination in only 63 (1.4 %) patients. 45 (1%) patients had previous COVID-19 infection. 854 (18%) flares were recorded during 20,287 patient-months (4,5/100 patient-months, median (IQR) follow up duration 4.3 (3.4, 5.5) months), of which 542 (11.7%) patients flared in the 3-month period of interest. Median (IQR) time to flare was 40 (18, 56) days (Figure 1). 134 (24.7%) flares were mild and self-limiting, 333 (61.4%) were mild-moderate and 75 (13.8%) were severe. 393 (72.5%) of those who flared required escalation of treatment and 30 (5.5%) required hospital admission. 545 (11.8%) had improved disease activity after the vaccine.

On multivariate Cox regression analysis, patients in the oldest age tertile [median (IQR) 72 (69, 77) years] were less likely to flare [HR 0.76 (95% CI 0.64, 0.90), p = 0.001] Patients with inflammatory arthritis (compared with connective tissue disease, vasculitis and others) and patients with baseline active disease were more likely to flare [HR 1.88 (95% CI 1.56, 2.25), p < 0.001 and 1.54 (95% CI 1.28, 1.85), p < 0.001 respectively] Gender, ethnicity and vaccine type were not significant predictors of flare. (Figure 2)

Conclusion: There was a moderately high rate of AIIRD flares after mRNA vaccination; however, there was no clustering of flares in the immediate post-vaccine period to suggest causality and severe flares were rare. Older patients were less likely to flare, while those with inflammatory arthritis and active disease at baseline were more likely to flare.

Supporting image 1

Table 1: Patient characteristics

Supporting image 2

Figure 1: Time to flare was examined using a Nelson Aalen cumulative hazard estimate

Supporting image 3

Figure 2: Predictors of disease flare using Cox proportional hazards analysis


Disclosures: M. Ma, Janssen, AbbVie/Abbott, Pfizer; A. Santosa, None; K. Kong, None; C. Xu, None; G. Teng, None; J. Tang, None; A. Mak, None; F. Tay, None; V. Ng, None; J. Koh, None; W. Fong, Novartis, Janssen, GlaxoSmithKlein(GSK); L. Chew, Pfizer, Pfizer, AbbVie/Abbott, Pfizer, AbbVie/Abbott, AbbVie/Abbott; A. Low, None; a. law, None; Y. Poh, None; S. Yeo, AbbVie/Abbott, Pfizer, Janssen; Y. Leung, AbbVie/Abbott, Janssen, Pfizer, DKSH; W. Goh, None; N. Roslan, None; T. Chuah, None; S. Angkodjojo, None; T. Arkachaisri, None; K. Teh, None; K. Phang, None; M. Sriranganathan, None; t. Tan, None; P. Cheung, Janssen, Boehringer-Ingelheim, Novartis, AbbVie/Abbott; M. Lahiri, AbbVie/Abbott, Janssen, DKSH.

To cite this abstract in AMA style:

Ma M, Santosa A, Kong K, Xu C, Teng G, Tang J, Mak A, Tay F, Ng V, Koh J, Fong W, Chew L, Low A, law a, Poh Y, Yeo S, Leung Y, Goh W, Roslan N, Chuah T, Angkodjojo S, Arkachaisri T, Teh K, Phang K, Sriranganathan M, Tan t, Cheung P, Lahiri M. Post-mRNA Vaccine Flares in Autoimmune Inflammatory Rheumatic Diseases: Results from the COronavirus National Vaccine Registry for ImmuNe Diseases SINGapore (CONVIN-SING) [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/post-mrna-vaccine-flares-in-autoimmune-inflammatory-rheumatic-diseases-results-from-the-coronavirus-national-vaccine-registry-for-immune-diseases-singapore-convin-sing/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/post-mrna-vaccine-flares-in-autoimmune-inflammatory-rheumatic-diseases-results-from-the-coronavirus-national-vaccine-registry-for-immune-diseases-singapore-convin-sing/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology